Every recall we track for Glenmark Pharmaceuticals Inc., USA — 141 in all — plus the complaints and injury reports the public filed about them.
Glenmark Pharmaceuticals recalls 15% Azelaic Acid Gel tubes with grainy texture. Product quality complaints reported for abnormal consistency. Check NDC 68462-626-52 and lot numbers for affected items.
Glenmark Pharmaceuticals recalls Alyacen birth control tablets with impurities. These pills may have unsafe levels of impurities that could affect safety. Stop using if you have the specific lot numbers listed.
Glenmark Pharmaceuticals recalls 4mg orally disintegrating ondansetron tablets due to blister packs not fully sealed, risking tablets falling out. Rx-only product sold in 30-tablet blister packs.
Glenmark Pharmaceuticals recalls 2.5mg/6.25mg Bisoprolol Fumarate and Hydrochlorothiazide tablets due to traces of ezetimibe found in some batches. Check NDC numbers for affected lots.
Glenmark Pharmaceuticals recalls 20 mg Nebivolol tablets due to cross contamination risk. Affected lots manufactured in India with specific expiration date. Consumers should check product details and contact for guidance.
Glenmark Pharmaceuticals recalls 15% Azelaic Acid Gel 50g for gritty texture complaints. Rx-only product with NDC 68462-626-52. Consumers should check batch numbers and contact for details.
Glenmark Pharmaceuticals recalls Viorele and Ethinyl Estradiol tablets due to failed impurities/degradation specs. These birth control pills may pose health risks if impurities are present. Check NDC 68462-318-29 and batch 20230733 for affected products.
Glenmark Pharmaceuticals recalls 400mg theophylline extended-release tablets with failed dissolution test results. These Rx-only tablets may not release medication properly over time. Consumers should contact the manufacturer for details.
Glenmark Pharmaceuticals recalls 25mg Carvedilol tablets due to nitrosamine impurity exceeding safe levels. This may pose health risks. Consumers should contact the company for details.
Glenmark Pharmaceuticals recalls 3.125 mg Carvedilol Tablets due to nitrosamine impurity exceeding safety levels. This may pose health risks. Affected products include 500-count and 100-count bottles with specific NDC numbers and expiration dates.
Glenmark Pharmaceuticals recalls 12.5 mg Carvedilol tablets due to nitrosamine impurity exceeding safe levels. Consumers with the specific NDC 68462-164-05 lot 19243202 should stop using and contact for details.
Glenmark Pharmaceuticals recalls 12.5 mg Carvedilol tablets with NNCI impurity above FDA limits. Affected lots manufactured in India, expiring June 2026. Stop using immediately.
Glenmark Pharmaceuticals recalls 25mg Carvedilol tablets due to NNCI impurity exceeding FDA limits. Affected lots manufactured in India for US sale. Consumers should contact pharmacy for safe alternatives.
Glenmark Pharmaceuticals recalls 10mg/40mg Ezetimibe and Simvastatin tablets due to impurity issues detected during long-term stability testing. Affected lots may pose risks if stored beyond expiration.
Glenmark recalls 600mg Theophylline Extended-Release Tablets due to OOS dissolution test results. Rx-only medication with specific batch numbers and expiration dates.
Glenmark Pharmaceuticals recalls 2.5mg Fluphenazine Hydrochloride tablets due to CGMP deviations. Affected units: 100-count bottles with NDC 68462-336-01, lot 17232214, expiring Sep 2025.
Glenmark Pharmaceuticals recalls 14mg Terif: CGMP deviations in manufacturing. Rx-only tablets may be unsafe. Check NDC# 68462-424-30 and lot # 17232462 for affected units.
Glenmark Pharmaceuticals recalls 10mg Solifenacin tablets due to CGMP deviations. Affected products include 30-count and 90-count bottles with specific NDC numbers. No remedy provided in official notice.
Glenmark Pharmaceuticals recalls 200mg Voriconazole tablets due to manufacturing deviations. Affected lots have specific expiration dates and NDC numbers. Consumers should check their product details and contact the manufacturer for guidance.
Glenmark Pharmaceuticals recalls 225mg extended-release capsules due to manufacturing deviations. This may affect safety in normal use. Check NDC# 68462-408-60 and lot # 17230819 for affected products.
Glenmark Pharmaceuticals recalls 50mg Lacosamide tablets due to manufacturing deviations. Affected products have specific NDC and lot numbers. Consumers should contact the company for details.
Glenmark Pharmaceuticals recalls 0.3mg nitroglycerin sublingual tablets due to CGMP deviations. Affected lots expire Nov 2025. Consumers should contact for details.
Glenmark Pharmaceuticals recalls 300mg clindamycin capsules due to CGMP deviations. Affected lots have specific expiration dates. Consumers should contact the company for details.
Glenmark Pharmaceuticals recalls 75mg Indomethacin Extended-Release Capsules due to CGMP deviations. Affected lots may pose quality risks; contact for details.
Glenmark Pharmaceuticals recalls 40mg Rosuvastatin tablets due to CGMP deviations. This affects specific batch numbers and expiration dates. Consumers should check their product details and contact the manufacturer for guidance.
Glenmark Pharmaceuticals recalls 325mg extended-release capsules due to manufacturing deviations. This may affect safety in normal use. Check NDC# 16714-826-01 and lot # 17230767 for affected products.
Glenmark Pharmaceuticals recalls 10mg Fluphenazine Hydrochloride tablets due to CGMP deviations. Affected units have NDC# 68462-338-01 and lot # 17232206. No specific remedy stated in recall notice.
Glenmark Pharmaceuticals recalls 200mg Lacosamide tablets due to manufacturing deviations. Affected lots expire April 2025. Consumers should contact the company for details.
Glenmark Pharmaceuticals recalls 120mg Diltiazem Hydrochloride Extended-Release Capsules due to CGMP deviations. Affected units have specific NDC and lot numbers. Consumers should contact the company for details.
Glenmark Pharmaceuticals recalls 80mg Pravastatin Sodium Tablets due to CGMP deviations. Affected lots may have quality issues; contact for return instructions.
Glenmark Pharmaceuticals recalls 200mg Rufinamide tablets due to CGMP deviations. This affects 120-count bottles with specific lot numbers. Consumers should contact the company for details.
Glenmark Pharmaceuticals recalls 225mg Propafenone Extended-Release Capsules due to CGMP deviations. Rx-only medication with specific lot numbers and expiration dates.
Glenmark Pharmaceuticals recalls 12.5mg Carvedilol tablets due to manufacturing deviations. Affected lots expire Jan 2026. Consumers should contact the company for details.
Glenmark Pharmaceuticals recalls 20mg Pravastatin tablets due to manufacturing deviations. Affected lots from March 2024 expire March 2026. Check NDC 16714-559-01 for details.
Glenmark Pharmaceuticals recalls 100mg Lacosamide tablets due to CGMP deviations. Affected units have specific lot numbers and expiration dates. Consumers should contact the manufacturer for details.
Glenmark Pharmaceuticals recalls 250mg/125mg acetaminophen-ibuprofen tablets with CGMP deviations. Products sold on Amazon/Walmart with specific lot numbers and expiration dates.
Glenmark Pharmaceuticals recalls 0.4mg nitroglycerin sublingual tablets due to CGMP deviations. Affected lots manufactured in India with specific expiration dates. Consumers should contact the company for details.
Glenmark Pharmaceuticals recalls 5mg Saxagliptin tablets (30-count and 90-count bottles) due to CGMP deviations. Rx-only medication with specific NDC numbers and expiration dates. Consumers should contact the manufacturer for details.
Glenmark Pharmaceuticals recalls 625mg Colesvelam Hydrochloride tablets due to CGMP deviations. Affected lots manufactured in India for US distribution. No specific remedy stated in recall notice.
Glenmark Pharmaceuticals recalls 50mg Voriconazole tablets due to CGMP deviations. This affects specific lot numbers and expiration dates. Consumers should contact the manufacturer for details.
Glenmark Pharmaceuticals recalls 325mg extended-release capsules due to manufacturing deviations. This may affect safety but no specific injury risk is described in the recall notice.
Glenmark Pharmaceuticals recalls 150mg Lacosamide tablets due to CGMP deviations. Affected units have specific lot numbers and expiration dates. Consumers should contact the manufacturer for details.
Glenmark Pharmaceuticals recalls 2.5mg Saxagliptin tablets due to CGMP deviations. Affected lots have specific NDC numbers and expiration dates. Consumers should contact the company for details.
Glenmark Pharmaceuticals recalls 10mg Prochlorperazine tablets due to manufacturing deviations. Affected products have specific NDC and lot numbers. Consumers should contact the company for details.
Glenmark Pharmaceuticals recalls 600mg gabapentin tablets (500-count bottles) due to CGMP deviations. These tablets may not meet quality standards. Consumers should check lot numbers and expiration dates on packaging.
Glenmark Pharmaceuticals recalls 5mg Solifenacin tablets due to CGMP deviations. These prescription-only tablets (30-count and 90-count bottles) may have manufacturing issues.
Glenmark Pharmaceuticals recalls 1000mg Metformin Hydrochloride Extended-Release Tablets due to CGMP deviations. Affected lots manufactured in India for US distribution. No specific remedy stated in recall notice.
Glenmark Pharmaceuticals recalls 20mg Pravastatin tablets due to CGMP deviations. Affected lots expire March 2026. No remedy specified in official notice.
Glenmark Pharmaceuticals recalls 550mg Naproxen Sodium Tablets (100-count) due to CGMP deviations. This may affect safety in manufacturing. Check NDC# 68462-179-01 and lot # 1723195: exp. date Aug 2025.
Glenmark Pharmaceuticals recalls 2.5mg Frov: CGMP deviations in manufacturing. Affected tablets may have quality issues. Stop using and contact for details.
Glenmark Pharmaceuticals recalls 67mg fenofibrate capsules due to CGMP deviations. This affects 100-count bottles with specific lot numbers and expiration dates.
Glenmark Pharmaceuticals recalls 80mg Pravastatin Sodium Tablets due to CGMP deviations. Affected lots expire by August 2025. No specific remedy stated in recall notice.
Glenmark Pharmaceuticals recalls 1000mg Ranolazine Extended-Release Tablets due to CGMP deviations. This affects 60-count bottles with NDC 68462-320-60, lot 17240040, expiring Dec 2025.
Glenmark Pharmaceuticals recalls 10mg cetirizine tablets due to CGMP deviations. Affected lots sold via Amazon and Walmart. Consumers should contact pharmacy for replacement.
Glenmark Pharmaceuticals recalls 100mg chlorpromazine hydrochloride tablets (NDC 68462-864-01) with a nitrosated impurity that may pose health risks. Affected lots 17232222 and 17232237 expire 10/31/2025.
Glenmark Pharmaceuticals recalls 6.25 mg Carvedilol Tablets due to unsafe nitroso impurity levels. Affected lots from 2023-2025; stop using immediately.
Glenmark Pharmaceuticals recalls Carvedilol 3.125mg tablets due to presence of N-Nitroso Carvedilol I impurity exceeding safe limits. Affected lots include 100-count and 500-count bottles with specific expiration dates.
Glenmark Pharmaceuticals recalls 12.5 mg Carvedilol tablets due to unsafe impurity levels. Affected lots expire April-June 2025. Stop using immediately if you have these specific batches.
Glenmark Pharmaceuticals recalls 25mg Carvedilol tablets due to unsafe impurity levels. Affected lots expire Feb 2025 or Jan 2026. Stop using immediately if you have these specific lots.
Glenmark Pharmaceuticals recalls 40mg Atomoxetine capsules due to N-Nitroso impurity exceeding FDA limits. Affected lots manufactured in Memphis, TN. Stop using immediately.
